• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Balm for Your Portfolio

For Rite Aid, patience is starting to pay off.
By GARY DVORCHAK
Oct 09, 2013 | 10:00 AM EDT
Stocks quotes in this article: RAD, WAG

Nearly 18 months ago, I recommended Rite-Aid (RAD) after I researched the stocks based on the recommendation of an extremely smart friend and insightful investor. (He is the chief financial officer of a publicly traded company, to boot!) As is often the case, patience is being rewarded. The stock treaded water for the next nine months, but Rite-Aid has been a rocket ship this year, with shares up nearly 500%. Naturally, that sort of appreciation raises the question of whether I should lock in profits or let my winners run.

Rite Aid (RAD) -- Daily
Source: Yahoo! Finance
View Chart » View in New Window »

As is usually the case when a stock is soaring, striking earnings performance is usually the cause. Rite-Aid recently reported blow-out earnings, with a 45% rise in earnings before interest, taxes, depreciation and amortization -- to $318 million -- in the second quarter. That's far ahead of the Street consensus of $238 million. Management also raised full-year guidance by 10% due to this momentum, and the company now expects to book more than $1.2 billion in EBITDA.

Strong results are really a margin story, since fiscal 2014 revenue expectations of $25.4 billion are not appreciably higher than the 2013 actual top line of $25.39 billion. Demonstrating the margin potential, second-quarter gross margin was up 132 basis points year over year. That came as more generic drugs, better front-end performance and cost controls squeezed more profit out of each revenue dollar. Low interest costs have not hurt, either, especially given Rite-Aid's still-high debt load. Interest expense declined 17% year over year despite debt that remained nearly flat.

Both pharmacy and front end are benefitting from good foot traffic. The thesis 18 months ago was that the Walgreen (WAG)-Express Scripts dispute would drive customer traffic to competitors, and Rite Aid has done a great job of retaining those customers. Management noted that the company has retained 75% of the customers gained from that period, and those customers are now being "monetized" as they visit the stores.

The positive 2014-and-beyond guidance is due in large part to the success of an ongoing store renovation program. Stores that have been refreshed into the "Wellness" concept are outperforming the corporate average in both pharmacy and front end, which indicates customer acceptance of the concept. Rite Aid expects to complete 1,200 remodels by the end of the fiscal year.

At $5, the share valuation is reasonable if future earnings only meet expectations. But, of course, if the company continues to blow out numbers, the stock could move higher. With enterprise value of around $10 billion against the EBITDA of $1.2 billion, the valuation is at around 8 -- probably a touch high for this industry and balance sheet.

So the stock could take a short-term breather. Still, there's the prospect of another wave of generic drugs coming on-market next year, the continuing Wellness store refresh, additional cost-cutting and interest expense reduction, as well as a (presumably) positive contribution from Obamacare. All of this should drive better-than-expected results for the next few quarters.

After its near-death experience in 2009, and several more years of "wandering in the wilderness," I am willing to let this one run a bit longer now that it is working.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Dvorchak had no positions in the stocks mentioned.

TAGS: Investing | U.S. Equity

More from Investing

Bearish Bets: 2 NYSE Stocks You Should Consider Shorting This Week

Bob Lang
Jan 24, 2021 10:30 AM EST

These names are displaying both quantitative and technical deterioration.

Price Targets: How They Mislead and How They Can be Used

James "Rev Shark" DePorre
Jan 23, 2021 10:00 AM EST

The main problem with price targets is that they are a static number in a dynamic situation.

Stock Market Continues to Defy Conventional Wisdom

James "Rev Shark" DePorre
Jan 22, 2021 5:04 PM EST

Concerns about the action being overheated remain, but rotational action keeps the momentum going.

AMC Is a High Risk, High Reward Play

Timothy Collins
Jan 22, 2021 2:15 PM EST

Short and sweet: This is based on the high running emotions of the markets. There's little to it beyond that.

GoodRx Needs a Shot in the Arm to Improve Its Outlook

Bruce Kamich
Jan 22, 2021 2:03 PM EST

IPOs in recent months have done extremely well -- not so GDRX.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:01 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    I discuss price targets in my Saturday column.
  • 07:54 AM EST GARY BERMAN

    Friday Morning Fibocall for 1/22/2021

    SPX (Long-Term View) The 1/21/21 NEW high @ 3861...
  • 11:16 AM EST CHRIS VERSACE

    Worst Stocks to Buy for the Biden Presidency

    Biden's take on the minimum wage, likely moves on ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login